Table 3.
Comparison of demographic and clinical results of survivors and nonsurvivors.
| Parameters | Survivor (n = 102) |
Nonsurvivor (n = 73) |
P value |
|---|---|---|---|
| Sex | |||
| Male | 59 (58%) | 46 (63%) | 0.491 |
| Female | 43 (42%) | 27 (37%) | |
| Age, y, (IQR) | 70 (60–80) | 76 (62–82) | 0.199 |
| Age (stratified) | |||
| ≤50 | 6 (6%) | 2 (3%) | 0.326 |
| 50–65 | 37 (36%) | 19 (26%) | 0.152 |
| ≥65 | 59 (58%) | 52 (71%) | 0.070 |
| 25 (OH)D, ng/mL, (IQR) | 6.88 (5–8.21) | 6.72 (5.66–8.31) | 0.421 |
| Corrected calcium, mg/dL, (IQR) | 8.29 (7.86–8.9) | 7.8 (7.5–8.3) | <0.001 |
| Phosphor, mg/dL, (IQR) | 3.1 (2.5–4) | 3 (2.2–4.1) | 0.623 |
| Magnesium, mg/dL, (IQR) | 1.92 (1.67–2.05) | 1.83 (−1.64–2.06) | 0.522 |
| Albumin, g/dL, (SD) | 2.86 (0.6) | 2.61 (0.55) | 0.005 |
| Urea, mg/dL, (IQR) | 47 (34–74) | 62 (28–91) | 0.575 |
| Creatine, mg/dL, (IQR) | 1.03 (0.79–1.53) | 1.11 (0.89–1.38) | 0.129 |
| AST, U/L, (IQR) | 24 (18–45) | 29 (17–45) | 0.569 |
| ALT, U/L, (IQR) | 22 (16–45) | 22 (14–40) | 0.157 |
| CRP, mg/dl, (IQR) | 7.57 (3.85–13.75) | 14.14 (10.57–17.41) | <0.001 |
| D-dimer, ug/L, (IQR) | 1200 (751–2950) | 1260 (731–2960) | 0.928 |
| Received high doses parenteral vitamin D3 | 70 (69%) | 43 (59%) | 0.185 |
| Length of stay, day, (IQR) | 9 (5–19) | 8 (6–16) | 0.685 |
| Endotracheal intubated | 15 (14%) | 60 (82%) | <0.001 |
Categorical data shown as number (percentage). Non-normally distributed continuous variables displayed as median (IQR). Chi-square test was used to analyze the categorical variables. Mann–Whitney’s test was used for nonparametric continuous variables.
25(OH) D 25-hydroxy vitamin D, IQR interquartile range, AST aspartate aminotransferase, ALT alanine aminotransferase, CRP C-reactive protein.
p < 0.05: significant (shown in bold).